Serial electropharmacologic studies in patients with ischemic heart disease and sustained ventricular tachyarrhythmias: When is drug testing sufficient?

Peter J. Kudenchuk, Blair Halperin, Jack Kron, Charles G. Walance, Karen K. Griffith, John H. McAnulty

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Serial testing of antiarrhythmic drugs by programmed electrical stimulation can be costly in time, expense and risk. The purpose of this study was to evaluate the results of serial electropharmacologic tests for similarities that might obviate the need for protracted drug testing. Serial electropharmacologic testing was performed in 283 patients with coronary artery disease and clinical sustained ventricular tachycardia (VT) or fibrillation (VF). Drug tests were defined as concordant if sustained VT or VF could be consistently induced, or failed to be consistently induced during all such trials in a given patient. The following drugs were included for testing: procainamide, quinidine and disopyramide (class IA); phenytoin, mexiletine and tocainide (class IB); and flecainide and encainide (class IC). All patients were serially tested with ≥2 (mean and median, 3) antiarrhythmic agents regardless of results from drug-free testing or initial acute drug testing. Overall, the results of serial drug trials directed by programmed stimulation were concordant in more than two thirds of patients. Concordance was comparably high whether patients were serially tested with drugs within the same antiarrhythmic class, or with drugs from differing classes, and was not related to patients' clinical or electrophysiologic characteristics. Protracted serial electropharmacologic testing does not appear necessary for predicting successful or unsuccessful antiarrhythmic drug therapy in survivors of clinical VT or VF. Single drug testing can identify most patients whose arrhythmia will or will not respond to medications.

Original languageEnglish (US)
Pages (from-to)1400-1405
Number of pages6
JournalThe American Journal of Cardiology
Volume72
Issue number18
DOIs
StatePublished - Dec 15 1993

Fingerprint

Tachycardia
Myocardial Ischemia
Pharmaceutical Preparations
Ventricular Tachycardia
Anti-Arrhythmia Agents
Encainide
Tocainide
Mexiletine
Flecainide
Disopyramide
Procainamide
Quinidine
Phenytoin
Ventricular Fibrillation
Electric Stimulation
Survivors
Cardiac Arrhythmias
Coronary Artery Disease
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Serial electropharmacologic studies in patients with ischemic heart disease and sustained ventricular tachyarrhythmias : When is drug testing sufficient? / Kudenchuk, Peter J.; Halperin, Blair; Kron, Jack; Walance, Charles G.; Griffith, Karen K.; McAnulty, John H.

In: The American Journal of Cardiology, Vol. 72, No. 18, 15.12.1993, p. 1400-1405.

Research output: Contribution to journalArticle

Kudenchuk, Peter J. ; Halperin, Blair ; Kron, Jack ; Walance, Charles G. ; Griffith, Karen K. ; McAnulty, John H. / Serial electropharmacologic studies in patients with ischemic heart disease and sustained ventricular tachyarrhythmias : When is drug testing sufficient?. In: The American Journal of Cardiology. 1993 ; Vol. 72, No. 18. pp. 1400-1405.
@article{660282c159ea4254903b8caa72c63859,
title = "Serial electropharmacologic studies in patients with ischemic heart disease and sustained ventricular tachyarrhythmias: When is drug testing sufficient?",
abstract = "Serial testing of antiarrhythmic drugs by programmed electrical stimulation can be costly in time, expense and risk. The purpose of this study was to evaluate the results of serial electropharmacologic tests for similarities that might obviate the need for protracted drug testing. Serial electropharmacologic testing was performed in 283 patients with coronary artery disease and clinical sustained ventricular tachycardia (VT) or fibrillation (VF). Drug tests were defined as concordant if sustained VT or VF could be consistently induced, or failed to be consistently induced during all such trials in a given patient. The following drugs were included for testing: procainamide, quinidine and disopyramide (class IA); phenytoin, mexiletine and tocainide (class IB); and flecainide and encainide (class IC). All patients were serially tested with ≥2 (mean and median, 3) antiarrhythmic agents regardless of results from drug-free testing or initial acute drug testing. Overall, the results of serial drug trials directed by programmed stimulation were concordant in more than two thirds of patients. Concordance was comparably high whether patients were serially tested with drugs within the same antiarrhythmic class, or with drugs from differing classes, and was not related to patients' clinical or electrophysiologic characteristics. Protracted serial electropharmacologic testing does not appear necessary for predicting successful or unsuccessful antiarrhythmic drug therapy in survivors of clinical VT or VF. Single drug testing can identify most patients whose arrhythmia will or will not respond to medications.",
author = "Kudenchuk, {Peter J.} and Blair Halperin and Jack Kron and Walance, {Charles G.} and Griffith, {Karen K.} and McAnulty, {John H.}",
year = "1993",
month = "12",
day = "15",
doi = "10.1016/0002-9149(93)90187-H",
language = "English (US)",
volume = "72",
pages = "1400--1405",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "18",

}

TY - JOUR

T1 - Serial electropharmacologic studies in patients with ischemic heart disease and sustained ventricular tachyarrhythmias

T2 - When is drug testing sufficient?

AU - Kudenchuk, Peter J.

AU - Halperin, Blair

AU - Kron, Jack

AU - Walance, Charles G.

AU - Griffith, Karen K.

AU - McAnulty, John H.

PY - 1993/12/15

Y1 - 1993/12/15

N2 - Serial testing of antiarrhythmic drugs by programmed electrical stimulation can be costly in time, expense and risk. The purpose of this study was to evaluate the results of serial electropharmacologic tests for similarities that might obviate the need for protracted drug testing. Serial electropharmacologic testing was performed in 283 patients with coronary artery disease and clinical sustained ventricular tachycardia (VT) or fibrillation (VF). Drug tests were defined as concordant if sustained VT or VF could be consistently induced, or failed to be consistently induced during all such trials in a given patient. The following drugs were included for testing: procainamide, quinidine and disopyramide (class IA); phenytoin, mexiletine and tocainide (class IB); and flecainide and encainide (class IC). All patients were serially tested with ≥2 (mean and median, 3) antiarrhythmic agents regardless of results from drug-free testing or initial acute drug testing. Overall, the results of serial drug trials directed by programmed stimulation were concordant in more than two thirds of patients. Concordance was comparably high whether patients were serially tested with drugs within the same antiarrhythmic class, or with drugs from differing classes, and was not related to patients' clinical or electrophysiologic characteristics. Protracted serial electropharmacologic testing does not appear necessary for predicting successful or unsuccessful antiarrhythmic drug therapy in survivors of clinical VT or VF. Single drug testing can identify most patients whose arrhythmia will or will not respond to medications.

AB - Serial testing of antiarrhythmic drugs by programmed electrical stimulation can be costly in time, expense and risk. The purpose of this study was to evaluate the results of serial electropharmacologic tests for similarities that might obviate the need for protracted drug testing. Serial electropharmacologic testing was performed in 283 patients with coronary artery disease and clinical sustained ventricular tachycardia (VT) or fibrillation (VF). Drug tests were defined as concordant if sustained VT or VF could be consistently induced, or failed to be consistently induced during all such trials in a given patient. The following drugs were included for testing: procainamide, quinidine and disopyramide (class IA); phenytoin, mexiletine and tocainide (class IB); and flecainide and encainide (class IC). All patients were serially tested with ≥2 (mean and median, 3) antiarrhythmic agents regardless of results from drug-free testing or initial acute drug testing. Overall, the results of serial drug trials directed by programmed stimulation were concordant in more than two thirds of patients. Concordance was comparably high whether patients were serially tested with drugs within the same antiarrhythmic class, or with drugs from differing classes, and was not related to patients' clinical or electrophysiologic characteristics. Protracted serial electropharmacologic testing does not appear necessary for predicting successful or unsuccessful antiarrhythmic drug therapy in survivors of clinical VT or VF. Single drug testing can identify most patients whose arrhythmia will or will not respond to medications.

UR - http://www.scopus.com/inward/record.url?scp=0027134926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027134926&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(93)90187-H

DO - 10.1016/0002-9149(93)90187-H

M3 - Article

C2 - 8256734

AN - SCOPUS:0027134926

VL - 72

SP - 1400

EP - 1405

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 18

ER -